vVARDIS has announced that more than one million teeth and more than 420,000 patients have been treated in the US since Jan 2024 with Curodont, its drill-free solution for early stage tooth decay, making it one of the fastest growing dental care product in its category.
Nearly 80% of all dental patients have early tooth decay. Oral health is an important aspect of overall health, and poor oral health, including untreated decay, can become life-threatening. With Curodont, dental teams have a drill-free solution to treat tooth decay at an early stage.
Curodont represents a true win-win proposition: patients benefit from a quick, needle- and drill-free treatment, while dental professionals can treat early decay within minutes — eliminating the need for a follow-up appointment and freeing up chair time for more complex procedures.
“Now that Curodont is available in nearly 10 percent of US dental offices, an increasing number of dental professionals — or ‘Curodontists’ — are embracing our treatment and giving patients access to this revolutionary solution,” said Dr Haley Abivardi, DMD, co-CE, and co-founder of vVARDIS. “Such high-speed adoption shows how dental professionals have been waiting for decades for a solution that enables them to treat tooth decay at an early stage.”
Dr Goly Abivardi, DMD, co-CEO and co-founder of vVARDIS, said: “We are thrilled to witness a ground-breaking transformation in dentistry similar to the advancements that medicine embraced years ago toward non-invasive, early intervention approaches. In the same way, Curodont is helping to elevate the standard of care for the early treatment of cavities.”
With more than 25 years of science, vVARDIS’ Curodont is backed by universities internationally and has earned the endorsement of renowned thought leaders, clinical experts, and innovators across the dental profession. vVARDIS’s Curodont products are currently available in the US and Europe and will continue to roll out globally.
